

1 **Association between BMI and cause-specific long-term mortality**
2 **in acute myocardial infarction patients.**

3

4 Timo Schmitz¹, Dennis Freuer¹, Philip Raake², Jakob Linseisen¹, Christa Meisinger¹

5

6 ¹ Epidemiology, Medical Faculty, University of Augsburg, Augsburg, Germany

7 ² University Hospital Augsburg, Department of Cardiology, Respiratory Medicine and Intensive Care,
8 Augsburg, Germany

9

10 ***Corresponding author:***

11 Dr. Timo Schmitz,

12 Epidemiology, Medical Faculty, University of Augsburg, Augsburg, Germany

13 Stenglinstraße 2

14 86156 Augsburg

15 Germany

16 Email: timo.schmitz@med.uni-augsburg.de

17 Tel.: +49 821-400-4506

18

19 **Abstract**

20 *Background:* To investigate the association between body mass index (BMI) at acute
21 myocardial infarction (AMI) and all-cause as well as cause-specific long-term mortality.

22 *Methods:* The analysis was based on 10,651 hospitalized AMI patients (age 25-84 years)
23 recorded by the population-based Myocardial Infarction Registry Augsburg between 2000 and
24 2017. The median follow-up time was 6.7 years [IQR: 3.5-10.0]. Cause-specific mortality
25 was obtained by evaluating the death certificates. In multivariable-adjusted COX regression
26 models using cubic splines for the variable BMI, the association between BMI and
27 cause-specific mortality (all-cause, cardiovascular, ischemic heart diseases, cancer) was
28 investigated. Additionally, a subgroup analysis in three age groups was performed for
29 all-cause mortality.

30 *Results:* Overall, there was a statistically significant U-shaped association between BMI at
31 AMI and long-term mortality with the lowest hazard ratios (HR) found for BMI values between
32 25 and 30 kg/m². For cancer mortality, higher BMI values > 30 kg/m² were not associated with
33 higher mortality. In patients aged <60 years, there was a significant association between BMI
34 values > 35 kg/m² and increased all-cause mortality; this association was missing in 60 to 84
35 years old patients. For all groups and for each specific cause of mortality, lower BMI (<
36 25kg/m²) values were significantly associated with higher mortality.

37 *Conclusions:* Overall, a lower BMI – and also a high BMI in patients younger than 60 years -
38 seem to be a risk factors for increased all-cause mortality after AMI. A BMI in a mid-range
39 between 25 and 30 kg/m² is favorable in terms of long-term survival after AMI.

40

41 **Key words:** BMI, acute myocardial infarction, long-term mortality, cause-specific mortality

42

43 **What is Known?**

- 44 • Obesity is considered a major risk factor for cardiovascular diseases and coronary artery
45 disease.
- 46 • Nonetheless, the results of prior studies indicated lower mortality for overweight and obese
47 individuals after acute myocardial infarction (AMI); a phenomenon often called ‘obesity
48 paradox’.

49 **What the Study Adds**

- 50 • This study analyzed the association between body mass index (BMI) and cause-specific
51 long-term mortality after AMI in a population-based cohort of 10.000 AMI patients recorded
52 by the Myocardial Infarction Registry Augsburg.
- 53 • The obesity paradox was partially confirmed, as we found a U-shaped association between
54 BMI and long-term mortality with the lowest risk of mortality in overweight individuals.
- 55 • For cancer mortality and in elderly, obesity (BMI > 30 kg/m²) was not associated with
56 mortality. Lower BMI < 25 kg/m² went along with significantly higher mortality in all age
57 groups and for all causes of death (all-cause, cardiovascular, ischemic heart disease, cancer)

58

59

60 ***1. Introduction***

61 Extreme body mass indices (BMI) are known to be a major risk factor for several diseases.
62 Very low BMI (e.g. in anorexia or cancer cachexia) as well as very high values in obese
63 individuals go along with increased risk of mortality¹⁻³. Especially obesity is considered to be
64 an important risk factor for metabolic diseases like diabetes mellitus and, closely linked to
65 that, a risk factor for several cardiovascular diseases as well⁴⁻⁶. However, for patients with
66 coronary artery disease (CAD) or acute myocardial infarction, prior studies have reported
67 conflicting results regarding the association between high BMI values and long-term
68 mortality: Some researchers found decreased mortality for patients with obesity, often
69 referred to as the ‘obesity paradox’⁷⁻¹⁴; a phenomenon that was questioned by the results of
70 several other studies^{15,16}. Thus, the true nature of the association between BMI and long-term
71 mortality in AMI survivors remains controversial. The present study aims to contribute to a
72 clearer and deeper understanding of this complex relationship. To do so, a large unselected
73 sample with high quality data is required, which in this case is derived from the
74 population-based Myocardial Infarction Registry Augsburg. Next to BMI and all-cause
75 mortality, there is also a lack of knowledge on the association between BMI and
76 cause-specific mortality, like cardiovascular diseases (CVD) mortality, ischemic heart disease
77 mortality or cancer mortality. Finally, the impact of age on the associations between BMI and
78 mortality will be investigated.

79

80 ***2. Methods***

81 **2.1 Study population**

82 The study used data from the Myocardial Infarction Registry in Augsburg. It was initially
83 established in 1984 as part of the World Health Organization (WHO) project MONICA
84 (Monitoring Trends and Determinants in Cardiovascular Disease). For almost 40 years, all
85 cases of non-fatal AMI and coronary deaths in the study region (city of Augsburg and the two
86 adjacent counties, approximately 680,000 inhabitants) were registered. Inclusion criteria for
87 patients were: primary residence in the study region and age between 25 and 74 years (until
88 2008) and 25-84 years (from 2009-2017), respectively.

89 Detailed information on case identification, classification and quality control of the data can be
90 found in a previous publication ¹⁷. All study participants gave written informed consent.
91 Methods of data collection and questionnaires have been approved by the ethics committee of
92 the Bavarian Medical Association (Bayerische Landesärztekammer) and the study was
93 performed in accordance with the Declaration of Helsinki. The study was registered at the
94 German Register of Clinical Studies (DRKS, project number DRKS00029042).

95 **2.2 Data collection**

96 During their hospital stays, patients were interviewed by trained study nurses using a
97 standardized questionnaire. Additionally, the patients' medical chart was reviewed in detail to
98 confirm the information obtained by the interview and to collect additional data. By this
99 procedure, a wide range of demographic data, data on cardiovascular risk factors, medical
100 history, comorbidities, laboratory values, diagnostics, treatment and medication were
101 collected for each patient.

102 In particular, information about body weight and height were obtained from the patient's
103 medical file. The variable BMI was calculated as weight in kg divided by the squared height
104 in meters. Renal function according to the estimated glomerular filtration rate (eGFR) was
105 calculated using the CKD-EPI formula.

106 **2.3 Outcome**

107 The outcome of this study was all-cause and cause-specific long-term mortality. Mortality
108 was ascertained by regularly checking the vital status of all registered AMI patients in
109 cooperation with the regional population registries. Death certificates were obtained from
110 local health departments. Additionally, for each deceased patient, a standardized questionnaire
111 was sent out to the former general practitioner and/or coroner. The questionnaire includes,
112 among other topics, questions about preexisting comorbidities and diseases, circumstances of
113 the acute event (e.g., reanimation) and specific medication. The main cause of death, encoded
114 by the ICD-10 classification^{18,19}, was determined on the base of the death certificate. CVD
115 deaths included all deaths encoded by I00 to I99, ischemic heart diseases were defined as
116 deaths encoded by I20 to I25 and finally, cancer deaths included the ICD-10 codes C00 to
117 D48.

118 **2.4 Statistical analysis**

119 For categorical variables, the results were presented as absolute frequencies with percentages
120 and the Chi-square test was used to test for differences between groups. For
121 normally-distributed continuous variables, the results were presented as means with standard
122 deviations and we used Student's t-tests to test for differences. For non-normally distributed

123 continuous variables the results were presented as medians with inter-quartiles ranges and
124 nonparametric tests were applied.

125 As there was no follow-up information on BMI over time, we limited the post-AMI
126 observational time to 10 years; patients with longer observational times were censored after
127 10 years. To concentrate on long-term mortality, all patients with an observational time of 28
128 days and less (the common definition of short-term mortality in the Augsburg Myocardial
129 Infarction Registry is death within 28 days after AMI) were excluded from the analysis.

130 ***2.5 COX regression analyses***

131 Multivariable-adjusted COX proportional hazard regression models were used to analyze the
132 association between BMI and all-cause and cause-specific long-term mortality (CVD
133 mortality, ischemic heart disease (IHD) mortality and cancer mortality). The relationship
134 between BMI and mortality was modeled using restricted cubic splines (RCS) with 4 knots (at
135 the 5th, 35th, 65th and 95th percentiles), which allows to capture a potential non-linear
136 association; the reference BMI value was set to 27.5 kg/m². The models were adjusted for the
137 continuous variable age (in years) and the categorical variables sex (male/female), diabetes
138 (yes, no), hypertension (yes, no), smoking (current, ex-smoker, never smoker, smoking status
139 unknown), renal function according to eGFR (≥ 60 ml/min, 30-59ml/min, < 30 ml/min,
140 unknown), left-ventricular ejection fraction (EF) ($\leq 30\%$, $>30\%$, unknown), type of infarction
141 (STEMI, NSTEMI, other/unknown), percutaneous coronary intervention (PCI) (yes, no) and
142 bypass therapy (yes, no).

143 The proportional hazard assumptions were checked graphically by inspecting the Kaplan
144 Meier survival curves as well as log(-log(survival)) plots; for the continuous variables BMI
145 and age the survival curves stratified for the corresponding quartiles were inspected.

146 In a subgroup analysis, we calculated the COX regression models stratified for three age
147 groups: age < 60 years between 60 and 74 years, and ≥ 74 years.

148 Furthermore, we calculated all models not using splines, but quartiles for the variable BMI
149 (displayed in the supplementary material). Finally, we performed two sensitivity analyses:
150 First, we calculated the COX model for the outcome ‘cancer mortality’ only including cases
151 with a follow-up time of two years and more (also excluding deaths within the first 2 years).
152 Second, we calculated all models only for patients who never smoked cigarettes (also
153 displayed in the supplementary material).

154 All statistical analyses were carried out with the R program version 4.3.2. A p value of < 0.05
155 was considered as statistically significant.

156

157 **3. Results**

158 Baseline characteristics of the study sample were displayed in table 1. The mean age was 63.7
159 (11.1) years and 73.3% of all patients were men. During the observational time of up to ten
160 years, 2,770 deaths were recorded among the 10,651 AMI patients. In total, 1,435 (51.8%)
161 deaths were classified as CVD deaths, 1,042 (37.6%) deaths were due to ischemic heart disease
162 and 577 (20.8%) due to cancer. Elderly patients ≥ 75 years were less likely to die because of
163 cancer and had more comorbidities (diabetes, hypertension, impaired renal function) compared

164 to AMI patients < 75 years; the percentage of current smokers decreased from 58.0% among
165 patients < 60 years to only 7.0% in the group ≥ 75 years. PCI was performed in 70.5% of all
166 cases, with the highest frequency in the age group < 60 years and the lowest frequency among
167 the elderly, aged ≥ 75 years.

168 ***3.1 All-cause and cause-specific mortality - total sample***

169 There was a U-shaped association between BMI and long-term all-cause mortality in the total
170 sample (figure 1A). Compared to the reference BMI value of 27.5 kg/m², patients with a BMI of
171 20 kg/m² had a highly increased risk of mortality (HR 2.14 [1.91,2.40]); patients with BMI
172 values of 25 and 30 kg/m² had HRs of 1.04 [0.99,1.10] and 1.08 [1.03,1.14] respectively. Obese
173 patients again had an increased risk of mortality with HRs of 1.22 [1.12,1.33] and 1.36
174 [1.15,1.61]. Table S1 displays HR values and 95%CI for specific BMI values and for each
175 outcome). The U-shaped relation for all-cause mortality was confirmed by the COX model
176 using BMI quartiles: the first and the fourth quartile had significantly higher HR values
177 compared to the second quartile (reference group) (supplementary table S2). A similar result
178 was obtained for CVD mortality (figure 1B). For ischemic heart diseases there appeared to be a
179 U-shaped association as well (figure 1C), but the results were no longer significant for high
180 BMI values. A different constellation was found for cancer mortality: low BMI levels were still
181 strongly associated with higher mortality, but for patients with high BMI values we didn't
182 observe a higher cancer mortality risk (figure 1D).

183 ***3.2 All-cause mortality in different age groups***

184 For the age group < 60 years, there was a pronounced U-shaped association between BMI and
185 all-cause mortality (figure 2A). Nevertheless, in the regression model using BMI quartiles, only

186 the first, but not the fourth BMI quartile was significantly associated with mortality compared
187 to the second quartile (reference), see table S2. In the age group 60-74 years there was also a
188 U-shaped association (figure 2B) and a significant higher mortality for patients in the first and
189 fourth quartile, see table S2. For the elderly group ≥ 75 years however, higher BMI levels were
190 not associated with higher mortality (figure 2C and table S2). Hence, low BMI levels were
191 significantly associated with an elevated risk of dying for all age groups, (figure 2), but only for
192 AMI patients < 75 years high BMI values were also significantly associated with increased
193 mortality.

194 ***3.3 Sensitivity analyses***

195 Excluding all cases with an observational time of less than two years had only minor impact on
196 the association between BMI and cancer mortality, see table S2 and figure S1 (supplementary
197 material). Moreover, including only never smokers into the COX models had moderate effect
198 on the results: While the general shape of the associations between BMI and all-cause and
199 cause-specific mortality was confirmed (in particular lowest mortality for BMI between 25 and
200 30 kg/m^2), the strengths of the associations appeared to be moderately attenuated (in terms of
201 lower HR values compared to the main models), see figures S2 and S2, supplementary material.

202

203 ***4. Discussion***

204 In this study, we found an overall U-shaped association between BMI and long-term mortality
205 after AMI. For the older age group (>75 years) as well as for cancer mortality, however, high
206 BMI values were not associated with higher risk for early mortality.

207 *High BMI values and long-term mortality*

208 Several prior studies have examined the relationship between (high) BMI and long-term
209 mortality after myocardial infarction, and thereby reporting conflicting results. Some studies
210 and meta-analyses indicated a survival benefit for patients with higher BMI in CAD, acute
211 coronary syndrome and AMI⁷⁻¹⁴; a phenomenon often referred to as the ‘obesity paradox’.
212 This phenomenon is only partially confirmed by the present study, as we found the lowest
213 mortality for patients with BMI values between 25 and 30 kg/m², which is categorized as
214 ‘pre-obesity’ or ‘overweight’ by the WHO classification²⁰. For BMI > 30 kg/m², which is
215 classified as obesity, mortality began to increase. These observations are supported by a
216 recent study from Sweden analyzing over 25,000 STEMI patients; they found the lowest
217 1-year all-cause mortality for the overweight group (BMI 25.0–29.9 kg/m²)²¹.

218 In fact, there are prior studies and meta-analyses that question this ‘obesity paradox’ in CAD
219 and AMI patients^{15,16}. One example is a recent study by Al-Shaar et al.¹⁶; they found higher
220 mortality for patients with higher BMI for all-cause and CVD mortality, which is in line with
221 our results.

222 The ‘obesity paradox’ would somehow contradict the concept of overweight and obesity
223 being a strong risk factor for the development of cardiovascular diseases. Our results actually
224 suggest that obesity with BMI > 30 kg/m² is also a risk factor for increased mortality in AMI
225 patients and in this sense consistent with the concept of obesity being a cardiovascular risk
226 factor not only in primary (and secondary), but also in tertiary prevention.

227 *Low BMI values and long-term mortality*

228 In prior publications it has been reported, that lower BMI $< 25 \text{ kg/m}^2$ is associated with
229 increased long-term mortality in CAD and AMI ^{7,8,11,12,21,22}, which is well in line with the
230 results of the present study. However, there are studies reporting contradicting results ¹⁶. In
231 the above mentioned study by Al-Shaar et al. for instance, lower BMI values were only
232 non-significantly associated with slightly increased mortality ¹⁶. They speculated, that this
233 might be an artifact caused by unintentional weight loss due to preexisting disease (reverse
234 causation). Especially, patients with preexisting cancer might drive this potential reverse
235 causation, which also might be applicable to the present study. However, our results were very
236 clear in this respect: we observed a higher mortality for lower BMI not only for all-cause and
237 cancer mortality, but also for CVD mortality and IHD mortality. Moreover, we performed a
238 sensitivity analysis for cancer mortality by excluding all patients with an observational time
239 of less than 2 years, thus excluding patients with preexisting, severe and advanced underlying
240 diseases such as cancer. But still, BMI values $< 25 \text{ kg/m}^2$ were strongly associated with
241 higher mortality. Therefore, the here reported associations between lower BMI and higher
242 mortality are regarded as valid and important findings.

243 *All-cause mortality and age groups*

244 While there was a pronounced U-shaped association between BMI and all-cause mortality for
245 AMI patients younger than 60 years, there was no association between higher BMI values and
246 mortality in the elderly group. We can only speculate about the reason for this observation:
247 Younger AMI patients have a higher life expectancy after their infarction compared to older
248 patients. Prior studies reported that a longer duration of obesity is associated with increased
249 risk of developing secondary diseases like diabetes mellitus ^{23,24} or CDV ²⁵. So, obesity might

250 reveal more distinct impacts on health in younger patients, who live long enough to develop
251 secondary conditions and are more likely to be affected by life-threatening complications.
252 Older patients in their seventies and eighties on the other hand often struggle to keep their
253 weight: Many are especially affected by sarcopenia, which impacts on bodily functions,
254 including the immune response to infections ²⁶. Thus, at older age, a higher BMI likely
255 represent higher muscle mass and bigger energy reserves and consequently less frailty. This
256 circumstance might annihilate the effect of obesity-related complications like diabetes and
257 CVD and consequently leading to comparable mortality for obese AMI patients compared to
258 individuals with BMI < 30 kg/m².

259 *Mortality and smoking*

260 Many prior studies indicated effects of residual confounding by smoking and/or an interaction
261 between BMI and smoking in mortality analyses ^{3,16,27-29}. This appears to be not much of a
262 surprise as smoking suppresses appetite which consequently can result in a relevant weight
263 reduction ³⁰. At the same time, smoking causes premature mortality since cigarette smoke
264 contains a variety of carcinogenic compounds ³¹ and is involved in the pathophysiology of
265 arteriosclerosis ^{32,33}. To reflect this circumstance, we adjusted all models for the smoking
266 status of the patients. Moreover, we performed a sensitivity analyses only including patients
267 who never smoked cigarettes. This had moderate impact on the associations observed, and the
268 overall shape of the associations was quite similar. Although smoking might be an important
269 factor or confounder regarding the association between BMI and long-term mortality, the
270 results found in this study appear to be applicable mainly independent of the smoking status
271 (even though the effect sizes (HR's) were attenuated).

272 *Strengths and Limitations*

273 The present study uses data from the population-based Myocardial Infarction Registry
274 Augsburg with complete enrollment, which minimizes selection bias and ensure highest data
275 quality. The number of included AMI cases is high and the follow up of patients is long with
276 a median observational time of 6.7 years. The broad variety of information on comorbidities,
277 treatment etc. enabled the calculation of most complete multivariable-adjusted COX
278 regression models. A particular strength of this study is information on the main cause of
279 death and separate analyses for specific types of mortality.

280 Nevertheless, there are also some limitations to mention. First, information on BMI was only
281 available for the time of infarction, and there was no follow-up information on BMI. BMI
282 might have changed considerable over the course of up to ten years. Indeed, body-weight
283 fluctuations are quite common³⁴ and go along with increased mortality in CAD and AMI
284 patients^{34,35}. Additionally, measures of body composition, like ‘percentage of body fat’ or
285 ‘body fat distribution’ might provide important additional information for the analysis of
286 obesity/body composition and mortality^{36,37}. Furthermore, over the course of 17 years, which
287 is the time frame for patient recruitment for this analysis, diagnostics, acute treatment and
288 prevention of coronary artery diseases and AMI has changed significantly (PCI treatment,
289 troponin diagnostics, medication, etc.), which may have affected the observed associations as
290 well. Our findings may not be generalized to all ethnic groups since no information on
291 ethnicity was available. Finally, we may have not considered all important confounders and
292 we cannot exclude reverse causation.

293 *5. Conclusion*

294 There is a general U-shaped association between BMI and all-cause mortality in AMI
295 patients. This association was most dominant in AMI patients < 60 years; in the elderly group
296 high BMI was not associated with increased mortality. For cancer mortality, only BMI values
297 < 25 kg/m² were associated with increased mortality; individuals with obesity (BMI >
298 30kg/m²) on the other hand were not more likely to die from cancer. We conclude that
299 patients with a mid-range BMI between 25 and 30 kg/m² have the most favorable outcome
300 after AMI; especially very low BMI values < 22 kg/m² are associated with higher mortality.

301

Acknowledgements:

We would like to thank all members of the Helmholtz Zentrum München, Institute of Epidemiology, and the Chair of Epidemiology at the University Hospital of Augsburg, who were involved in the planning and conduct of the study. Steering partners of the MI Registry, Augsburg, include the Chair of Epidemiology at the University Hospital of Augsburg and the Department of Internal Medicine I, Cardiology, University Hospital of Augsburg. Many thanks for their support go to the local health departments, the office-based physicians and the clinicians of the hospitals within the study area. Finally, we express our appreciation to all study participants.

Sources of Funding: This work was supported by the Helmholtz Zentrum München, German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education, Science, Research and Technology and by the State of Bavaria and the German Federal Ministry of Health. This research also received support from the Faculty of Medicine, University of Augsburg, and the University Hospital of Augsburg, Germany. Since the year 2000, the collection of MI data has been co-financed by the German Federal Ministry of Health to provide population-based MI morbidity data for the official German Health Report (see <http://www.gbe-bund.de> www.gbe-bund.de).

Conflict of interest: none declared

Authors' contribution: TS and CM conceived the study. TS performed the statistical analysis and drafted the manuscript. CM was responsible for the acquisition of the data and supervised the analysis. DF, PR and JL contributed to data acquisition and revised the manuscript. All authors approved the final manuscript.

Availability of data and materials: The datasets generated during and/or analysed during the current study are not publicly available due to data protection aspects but are available in an anonymized form from the corresponding author on reasonable request.

Ethics approval and consent to participate: Data collection of the MONICA/KORA MI registry has been approved by the ethics committee of the Bavarian Medical Association (Bayerische Landesärztekammer) and the study was performed in accordance with the Declaration of Helsinki. All study participants have given written informed consent.

References

1. Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK. *Lancet Diabetes Endocrinol*. 2018;6:944–953. doi: 10.1016/S2213-8587(18)30288-2
2. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. *JAMA*. 2013;309:71–82. doi: 10.1001/jama.2012.113905
3. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL, English DR, Folsom AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman-Bolton J, Hoppin JA, Koenig KL, Lee I-M, Linet MS, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jacquotte A, Willett WC, Thun MJ. Body-mass index and mortality among 1.46 million white adults. *N Engl J Med*. 2010;363:2211–2219. doi: 10.1056/NEJMoa1000367
4. Kachur S, Lavie CJ, Schutter A de, Milani RV, Ventura HO. Obesity and cardiovascular diseases. *Minerva Med*. 2017;108:212–228. doi: 10.23736/S0026-4806.17.05022-4
5. Tian X, Chen S, Wang P, Xu Q, Zhang Y, Luo Y, Wu S, Wang A. Insulin resistance mediates obesity-related risk of cardiovascular disease: a prospective cohort study. *Cardiovasc Diabetol*. 2022;21:289. doi: 10.1186/s12933-022-01729-9
6. Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, Yin X, Xu Q. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. *Front Endocrinol (Lausanne)*. 2023;14:1161521. doi: 10.3389/fendo.2023.1161521
7. Wang ZJ, Zhou YJ, Galper BZ, Gao F, Yeh RW, Mauri L. Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis. *Heart*. 2015;101:1631–1638. doi: 10.1136/heartjnl-2014-307119
8. Niedziela J, Hudzik B, Niedziela N, Gašior M, Gierlotka M, Wasilewski J, Myrda K, Lekston A, Poloński L, Rozentryt P. The obesity paradox in acute coronary syndrome: a meta-analysis. *Eur J Epidemiol*. 2014;29:801–812. doi: 10.1007/s10654-014-9961-9
9. Angerås O, Albertsson P, Karason K, Råmunddal T, Matejka G, James S, Lagerqvist B, Rosengren A, Omerovic E. Evidence for obesity paradox in patients with acute coronary syndromes: a report

- from the Swedish Coronary Angiography and Angioplasty Registry. *Eur Heart J*. 2013;34:345–353. doi: 10.1093/eurheartj/ehs217
10. Bucholz EM, Beckman AL, Krumholz HA, Krumholz HM. Excess weight and life expectancy after acute myocardial infarction: The obesity paradox reexamined. *Am Heart J*. 2016;172:173–181. doi: 10.1016/j.ahj.2015.10.024
 11. Paola L de, Mehta A, Pana TA, Carter B, Soiza RL, Kafri MW, Potter JF, Mamas MA, Myint PK. Body Mass Index and Mortality, Recurrence and Readmission after Myocardial Infarction: Systematic Review and Meta-Analysis. *J Clin Med*. 2022;11. doi: 10.3390/jcm11092581
 12. Kanic V, Vollrath M, Frank B, Kanic Z. An obesity paradox in patients with myocardial infarction undergoing percutaneous intervention. *Nutr Metab Cardiovasc Dis*. 2021;31:127–136. doi: 10.1016/j.numecd.2020.08.024
 13. Liu S-H, Lin Y-Z, Han S, Jin Y-Z. The obesity paradox in ST-segment elevation myocardial infarction patients: A meta-analysis. *Ann Noninvasive Electrocardiol*. 2023;28:e13022. doi: 10.1111/anec.13022
 14. Wang L, Liu W, He X, Chen Y, Lu J, Liu K, Cao K, Yin P. Association of overweight and obesity with patient mortality after acute myocardial infarction: a meta-analysis of prospective studies. *Int J Obes (Lond)*. 2016;40:220–228. doi: 10.1038/ijo.2015.176
 15. Chrysant SG, Chrysant GS. New insights into the true nature of the obesity paradox and the lower cardiovascular risk. *J Am Soc Hypertens*. 2013;7:85–94. doi: 10.1016/j.jash.2012.11.008
 16. Al-Shaar L, Li Y, Rimm EB, Manson JE, Rosner B, Hu FB, Stampfer MJ, Willett WC. Body Mass Index and Mortality Among Adults With Incident Myocardial Infarction. *Am J Epidemiol*. 2021;190:2019–2028. doi: 10.1093/aje/kwab126
 17. Löwel H, Meisinger C, Heier M, Hörmann A. The population-based acute myocardial infarction (AMI) registry of the MONICA/KORA study region of Augsburg. *Gesundheitswesen*. 2005;67 Suppl 1:S31-7. doi: 10.1055/s-2005-858241
 18. WHO. ICD-10 Version:2019 (WHO). <https://icd.who.int/browse10/2019/en>. Accessed January 12, 2024
 19. World Health Organization. International statistical classification of diseases and International statistical classification of diseases and related health problems - 10th revision. Fifth edition 2016.

- <https://iris.who.int/bitstream/handle/10665/246208/9789241549165-V1-eng.pdf>. Accessed January 12, 2024
20. WHO Europe. A healthy lifestyle - WHO recommendations.
<https://www.who.int/europe/news-room/fact-sheets/item/a-healthy-lifestyle---who-recommendations>. Accessed January 12, 2024
 21. Jamaly S, Redfors B, Omerovic E, Carlsson L, Karason K. Prognostic significance of BMI after PCI treatment in ST-elevation myocardial infarction: a cohort study from the Swedish Coronary Angiography and Angioplasty Registry. *Open Heart*. 2021;8. doi: 10.1136/openhrt-2020-001479
 22. Yokoyama H, Tomita H, Honda S, Nishihira K, Kojima S, Takegami M, Asaumi Y, Yamashita J, Saji M, Kosuge M, Takahashi J, Sakata Y, Takayama M, Sumiyoshi T, Ogawa H, Kimura K, Yasuda S. Effect of Low Body Mass Index on the Clinical Outcomes of Japanese Patients With Acute Myocardial Infarction - Results From the Prospective Japan Acute Myocardial Infarction Registry (JAMIR). *Circ J*. 2022;86:632–639. doi: 10.1253/circj.CJ-21-0705
 23. Abdullah A, Stoelwinder J, Shortreed S, Wolfe R, Stevenson C, Walls H, Courten M de, Peeters A. The duration of obesity and the risk of type 2 diabetes. *Public Health Nutr*. 2011;14:119–126. doi: 10.1017/S1368980010001813
 24. The NS, Richardson AS, Gordon-Larsen P. Timing and duration of obesity in relation to diabetes: findings from an ethnically diverse, nationally representative sample. *Diabetes Care*. 2013;36:865–872. doi: 10.2337/dc12-0536
 25. Amani-Beni R, Darouei B, Zefreh H, Sheikhabahaei E, Sadeghi M. Effect of Obesity Duration and BMI Trajectories on Cardiovascular Disease: A Narrative Review. *Cardiol Ther*. 2023;12:307–326. doi: 10.1007/s40119-023-00317-6
 26. Nelke C, Dziewas R, Minnerup J, Meuth SG, Ruck T. Skeletal muscle as potential central link between sarcopenia and immune senescence. *EBioMedicine*. 2019;49:381–388. doi: 10.1016/j.ebiom.2019.10.034
 27. Freedman DM, Sigurdson AJ, Rajaraman P, Doody MM, Linet MS, Ron E. The mortality risk of smoking and obesity combined. *Am J Prev Med*. 2006;31:355–362. doi: 10.1016/j.amepre.2006.07.022
 28. Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, Romundstad P, Vatten LJ. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort

- studies with 3.74 million deaths among 30.3 million participants. *BMJ*. 2016;353:i2156. doi: 10.1136/bmj.i2156
29. Global BMC, Di Angelantonio E, Bhupathiraju S, Wormser D, Gao P, Kaptoge S, Berrington de Gonzalez A, Cairns B, Huxley R, Jackson C, Joshy G, Lewington S, Manson J, Murphy N, Patel A, Samet J, Woodward M, Zheng W, Zhou M, Bansal N, Barricarte A, Carter B, Cerhan J, Smith G, Fang X, Franco O, Green J, Halsey J, Hildebrand J, Jung K, Korda R, McLerran D, Moore S, O'Keefe L, Paige E, Ramond A, Reeves G, Rolland B, Sacerdote C, Sattar N, Sofianopoulou E, Stevens J, Thun M, Ueshima H, Yang L, Yun Y, Willeit P, Banks E, Beral V, Chen Z, Gapstur S, Gunter M, Hartge P, Jee S, Lam T-H, Peto R, Potter J, Willett W, Thompson S, Danesh J, Hu F. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. *Lancet*. 2016;388:776–786. doi: 10.1016/S0140-6736(16)30175-1
30. Audrain-McGovern J, Benowitz NL. Cigarette smoking, nicotine, and body weight. *Clin Pharmacol Ther*. 2011;90:164–168. doi: 10.1038/clpt.2011.105
31. Hecht SS. Cigarette smoking: cancer risks, carcinogens, and mechanisms. *Langenbecks Arch Surg*. 2006;391:603–613. doi: 10.1007/s00423-006-0111-z
32. Siasos G, Tsigkou V, Kokkou E, Oikonomou E, Vavuranakis M, Vlachopoulos C, Verveniotis A, Limperi M, Genimata V, Papavassiliou AG, Stefanadis C, Tousoulis D. Smoking and atherosclerosis: mechanisms of disease and new therapeutic approaches. *Curr Med Chem*. 2014;21:3936–3948. doi: 10.2174/092986732134141015161539
33. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. *Arterioscler Thromb Vasc Biol*. 2014;34:509–515. doi: 10.1161/ATVBAHA.113.300156
34. Lopez-Jimenez F, Wu CO, Tian X, O'Connor C, Rich MW, Burg MM, Sheps D, Raczynski J, Somers VK, Jaffe AS. Weight change after myocardial infarction--the Enhancing Recovery in Coronary Heart Disease patients (ENRICH) experience. *Am Heart J*. 2008;155:478–484. doi: 10.1016/j.ahj.2007.10.026
35. Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-Weight Fluctuations and Outcomes in Coronary Disease. *N Engl J Med*. 2017;376:1332–1340. doi: 10.1056/NEJMoa1606148

36. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, Willett WC. Body Size and Fat Distribution as Predictors of Coronary Heart Disease among Middle-aged and Older US Men. *Am J Epidemiol*. 1995;141:1117–1127. doi: 10.1093/oxfordjournals.aje.a117385
37. Schutter A de, Lavie CJ, Patel DA, Artham SM, Milani RV. Relation of body fat categories by Gallagher classification and by continuous variables to mortality in patients with coronary heart disease. *Am J Cardiol*. 2013;111:657–660. doi: 10.1016/j.amjcard.2012.11.013

Figure 1: Association between BMI and all-cause and cause specific mortality in the total sample. The COX regression models were adjusted for age, sex, diabetes, hypertension, smoking status, eGFR, left-ventricular EF, type of infarction, PCI and bypass therapy.

Figure 2: Association between BMI and all-cause mortality in different age groups. The COX regression models were adjusted for age, sex, diabetes, hypertension, smoking status, eGFR, left-ventricular EF, type of infarction, PCI and bypass therapy.

Table 1: Baseline characteristics of patients with and without diabetes. Categorical data presented as total numbers (%). Numeric data is presented as mean (SD) or median (IQR).


| | Total sample (n= 10651) | Age groups | | | p-value |
|---|------------------------------------|-------------------------------------|-----------------------------------|---------------------------------|----------------|
| | | < 60 years (n = 3604) | 60-74 years (n = 5369) | ≥75 years (n = 1678) | |
| Sex (male) | 7809 (73.3) | 2961 (82.2) | 3846 (71.6) | 1002 (59.7) | <0.001 |
| Age (mean, sd) | 63.7 (11.1) | 50.9 (6.2) | 67.5 (4.3) | 78.9 (2.8) | <0.001 |
| BMI in kg/m ² (median, IQR) | 27.1 (24.5-30.1) | 27.5 (24.9 - 30.5) | 27.1 (24.5 - 30.1) | 26.3 (24.0 - 29.3) | <0.001 |
| Mortality | | | | | |
| Total number of deaths* (% of all cases) | 2770 (26.0) | 376 (10.4) | 1627 (30.3) | 767 (45.7) | <0.001 |
| CVD deaths* (% of all deaths) | 1435 (51.8) | 196 (52.1) | 829 (51.0) | 410 (53.5) | 0.515 |
| Ischemic heart disease deaths* (% of all deaths) | 1042 (37.6) | 155 (41.2) | 619 (38.0) | 268 (34.9) | 0.103 |
| Cancer deaths* (% of all deaths) | 591 (21.3) | 106 (28.2) | 369 (22.7) | 116 (15.1) | <0.001 |
| Comorbidities and clinical characteristics | | | | | |
| Diabetes mellitus | 3367 (31.6) | 809 (22.4) | 1893 (35.3) | 665 (39.6) | <0.001 |
| Hypertension | 8309 (78.0) | 2384 (66.1) | 4417 (82.3) | 1508 (89.9) | <0.001 |
| Smoking status | | | | | <0.001 |
| Current smoker | 3400 (31.9) | 2090 (58.0) | 1193 (22.2) | 117 (7.0) | |
| Ex-smoker | 3370 (31.6) | 815 (22.6) | 1953 (36.4) | 602 (35.9) | |
| Never smoker | 3265 (30.7) | 606 (16.8) | 1836 (34.2) | 823 (49.0) | |
| Smoking status unknown | 616 (5.8) | 93 (2.6) | 387 (7.2) | 136 (8.1) | |

| | | | | | |
|---------------------------|------------------|-------------|-------------|-------------|------------------|
| <i>Type of infarction</i> | <i><0.001</i> | | | | |
| - STEMI | 3849 (36.1) | 1620 (45.0) | 1802 (33.6) | 427 (25.4) | |
| - NSTEMI | 5637 (52.9) | 1767 (49.0) | 2958 (55.1) | 912 (54.4) | |
| - other/unknown | 1165 (10.9) | 217 (6.0) | 609 (11.3) | 339 (20.2) | |
| <i>Renal function</i> | <i><0.001</i> | | | | |
| - GFR \geq 60ml/min | 5530 (51.9) | 2271 (63.0) | 2542 (47.3) | 717 (42.7) | |
| - GFR 30-59ml/min | 1930 (18.1) | 186 (5.2) | 987 (18.4) | 757 (45.1) | |
| - GFR $<$ 30ml/min | 395 (3.7) | 38 (1.1) | 183 (3.4) | 174 (10.4) | |
| - GFR unknown | 2796 (26.3) | 1109 (30.8) | 1657 (30.9) | 30 (1.8) | |
| <i>Therapy</i> | | | | | |
| PCI | 7505 (70.5) | 2860 (79.4) | 3545 (66.0) | 1100 (65.6) | <i><0.001</i> |
| Bypass therapy | 1599 (15.0) | 401 (11.1) | 963 (17.9) | 235 (14.0) | <i><0.001</i> |


* All deaths occurring in the time period between 28 days until 10 years after AMI

Figure 1


A All-cause mortality - total sample



B CVD mortality



C Ischemic heart disease mortality



D Cancer mortality






Figure 2

A All-cause mortality - age group < 60 years



B All-cause mortality - age group 60-74 years



C All-cause mortality - age group ≥ 75 years

